Takeda's QDENGA becomes first dengue vaccine approved in India
Takeda's QDENGA has become the first dengue vaccine approved in India, a country that accounts for nearly one-third of the global dengue burden. The approval is critical as India's dengue cases have risen 11-fold in two decades. Takeda will partner with Biological E to produce 50 million doses annually. The vaccine protects against all four serotypes without requiring prior exposure or testing.
QDENGA regulatory approval
▪QDENGA is the first dengue vaccine to be approved in India.
▪Takeda Pharmaceutical's dengue vaccine, QDENGA, has been approved by India's drug regulator.
Vaccine characteristics
▪The QDENGA vaccine can be administered regardless of prior dengue exposure and does not require pre-vaccination testing.
▪QDENGA is a tetravalent live-attenuated vaccine designed to protect against all four dengue virus serotypes.
▪Long-term data for QDENGA demonstrated sustained protection against dengue disease and dengue-related hospitalization.
Dengue burden in India
▪India accounts for nearly one-third of the global dengue burden.
▪Reported dengue cases in India have increased 11-fold in the past two decades.
Manufacturing partnership
▪Takeda partnered with Indian vaccine maker Biological E in 2024 to expand manufacturing of QDENGA.
▪Indian vaccine maker Biological E plans to build capacity to produce 50 million doses of QDENGA annually.
▪Takeda aims to manufacture 100 million doses of QDENGA a year globally by the end of the decade.
Global distribution
▪More than 32 million doses of QDENGA have been distributed globally since the vaccine's launch.
▪Since its launch in 2022, QDENGA has been approved in 43 countries.
Story comments
Loading comments…